The drug has shown strong results in phase 3 clinical trials, which are the basis for the new application to the FDA.

Drugs such as Cobenfy could reshape the antipsychotic market, providing a more nuanced range of patient options.

As interest in psychedelic medicine grows, researchers have synthesized a decade of evidence to understand how ayahuasca ...